Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as Octavian Therapeutics to align with its “growth ambitions and its ...
Over the past six months, Octavian has sharpened its focus on small molecule drug discovery targeting the endocannabinoid system. Its lead candidate, a patent-protected small molecule new chemical ...
Over the past six months, Octavian has sharpened its focus on small molecule drug discovery targeting the endocannabinoid system. Its lead candidate, a patent-protected small molecule new chemical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback